A scholarship to foster future leaders in evidence based medicine

The inaugural 2019 Doug Altman Scholarship at EBMLive in Oxford

Georgia C Richards,¹ doctoral researcher, Helen Macdonald,² head of education, Peter J Gill,^{1,3} assistant professor of paediatrics and honorary fellow

¹Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK

²The BMJ, London

³Division of Pediatric Medicine, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada

Correspondence to: G Richards georgia.richards@phc.ox.ac.uk

Doug Altman (1948-2018) was *The BMJ*'s chief statistician for over 20 years. His work on improving the execution and reporting of research made him a world leader in evidence based medicine and a distinguished role model. Doug helped researchers design and report good quality studies to answer important clinical questions. His editorial, "The scandal of poor medical research," written in 1994 is essential reading for those new to evidence based medicine.¹ Its call for "less research, better research, and research done for the right reasons" remains relevant today. His passion for teaching and mentoring makes him a source of inspiration for early career researchers.

To commemorate his contribution and leadership to medical research, the EBMLive conference—a collaboration between Oxford's Centre for Evidence Based Medicine and *The BMJ*—is launching the inaugural Doug Altman Scholarship (see box). The scholarship encourages and supports future leaders in evidence based medicine by offering a valuable opportunity to early career researchers seeking to improve the quality of research and its use in clinical practice. Those who will shape the future of evidence based medicine need places to meet, learn, exchange ideas, be inspired, and help to inspire others. They also need a seat at the table, to hear what today's leaders have to say, to contribute to developments in medical research, and to learn how to lead.

In 2017, the evidence based medicine community, through EBMLive, launched the "evidence based medicine manifesto,"² a road map towards more trustworthy evidence that

pledges to “encourage the next generation of leaders in evidence based medicine.”³ The Doug Altman Scholarship is one way to support this commitment. The scholarship aims to reinforce the importance of mentorship, which was at the heart of Doug’s legacy and is still at the heart of the evidence based medicine movement.⁴

Several leaders in evidence based medicine emerged in the 1990s. Their shared enthusiasm for improving the development, appraisal, quality, and dissemination of medical research led to internationally influential initiatives such as the Cochrane Collaboration and the EQUATOR network.^{5 6} Since then, lives have been saved through the clinical application of synthesised and appraised evidence from randomised trials and systematic reviews, including the identification of harms from drugs, devices, and other medical interventions.⁷

Why do we need new leaders? Like most disciplines, evidence based medicine must refresh, develop, and rethink its direction as the evidence ecosystem, clinical medicine, and the world changes. Some commentators think that the movement is in “crisis.”^{8 9} Challenges such as reporting bias,¹⁰ poor regulation,¹¹ undeclared conflicts of interest¹² and an overemphasis on surrogate endpoints¹³ and statistical significance¹⁴ are unresolved. Developing effective solutions will require leadership, mentorship, and teamwork far into the future.

Evidence based medicine needs creative leaders who are open about the limitations of research and demand full transparency in the reporting of the benefits and harms of treatments. They will need to navigate the swiftly evolving landscape of medical research, including the shift towards “big data,”¹⁵ and remain sceptical to new, untested interventions. They will need to overcome major perverse incentives such as the culture of “publish or perish” in academic institutions and other systemic barriers that inhibit or fail to foster emerging leaders in medical research.

Improving the design, conduct, and reporting of medical research requires a wide range of individuals with diverse skills to think and work together. Doug Altman spoke about the need to attract expertise from all disciplines. He and the late Dave Sackett, another world leader in evidence based medicine, both emphasised the importance of collaborative opportunities and mentoring to their own careers,^{16 17} and diligently extended these benefits to others. One of Dave Sackett’s key achievements was to “infect the young” with the principles of evidence-based medicine by creating opportunities to learn and apply those principles. EBMLive is one such opportunity.

We encourage students, junior doctors, early career researchers, and patients from anywhere in the world to apply for the 2019 Doug Altman Scholarship. We welcome applicants from diverse backgrounds including academia, industry, publishing, government, healthcare, and advocacy to share their ideas on how to make evidence relevant and replicable for everyone. Doug Altman has left a legacy that will change the way we do research. This scholarship, in his honour, is our commitment to continue his extraordinary work.

Box start

The inaugural 2019 Doug Altman Scholarship, funded by the McCall MacBain Foundation, will waive EBMLive delegate fees for ten applicants, and the top submission will be awarded the full Doug Altman Scholarship. The scholarship will cover:

- travel to and from Oxford for the duration of EBMLive,
- three nights' accommodation in one of Oxford's colleges, and
- attendance at the conference dinner.

During the EBMLive conference, the Doug Altman Scholar and the nine shortlisted submissions will:

- present their ideas and participant in dedicated 'Future Leaders' sessions,
- contribute during debates,
- learn from leaders in evidence-based medicine,
- develop networks, and
- build a community of early career researchers.

Further details and how to apply can be found at <https://ebmlive.org/doug-altman/>.

Competing interests: "I/We have read and understood the BMJ Group policy on declaration of interests and declare the following interests: GCR receives funding from the NHS National Institute of Health Research (NIHR) School for Primary Care Research (SPCR), the Naji Foundation and the Rotary Foundation to study for a Doctor of Philosophy (DPhil) at the University of Oxford. She is a member of the 2019 EBMLive steering committee and has been working with members of the Centre for Evidence Based Medicine and *The BMJ* to develop the 2019 Doug Altman Scholarship. HM is part of the steering group of EBMLive. PJG has received grant funding from the Canadian Paediatric Society, and the Canadian Institute of Health Research (CIHR) in the past five years. He is on the CMAJ Editorial Advisory Board and on the Institute Advisory Board for the CIHR Institute of Human Development, Child and Youth Health (IHDCYH) where he has expenses reimbursed to attend meetings. He is on the editorial board of *BMJ Evidence Based Medicine*. He is a member of the 2019 EBMLive steering committee and has been working with members of the Centre for Evidence Based Medicine and *The BMJ* to develop the 2019 Doug Altman Scholarship, and he has expenses reimbursed to attend the conference.

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution,

iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above. **[Please confirm]** – yes I confirm this

Provenance and peer review: Commissioned, not peer reviewed.

<jrn>1 Altman DG. The scandal of poor medical research. *BMJ* 1994;308:283-4. [PubMed](#) doi:10.1136/bmj.308.6924.283 </jrn>

<jrn>2 Heneghan C, Mahtani KR, Goldacre B, Godlee F, Macdonald H, Jarvies D. Evidence based medicine manifesto for better healthcare. *BMJ* 2017;357:j2973. [PubMed](#) doi:10.1136/bmj.j2973</jrn>

<jrn>3 Heneghan C, Mahtani KR, Goldacre B, Godlee F, Macdonald H, Jarvies D. Evidence based medicine manifesto for better healthcare. *BMJ* 2017;357:j2973. [PubMed](#) doi:10.1136/bmj.j2973 </jrn>

<jrn>4 Sackett DL. On the determinants of academic success as a clinician-scientist. *Clin Invest Med* 2001;24:94-100. [PubMed](#)</jrn>

<jrn>5 Chalmers I, The Cochrane collaboration. The Cochrane collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. *Ann N Y Acad Sci* 1993;703:156-63, discussion 163-5. [PubMed](#) doi:10.1111/j.1749-6632.1993.tb26345.x </jrn>

<jrn>6 Altman DG, Simera I, Hoey J, Moher D, Schulz K. EQUATOR: reporting guidelines for health research. *Lancet* 2008;371:1149-50. [PubMed](#) doi:10.1016/S0140-6736(08)60505-X </jrn>

<eref>7 Academy of Medical Royal Colleges. Evidence based medicine matters. Sense About Science. 2013. <https://archive.senseaboutscience.org/data/files/resources/124/Evidence-Based-Medicine-Matters.pdf> (accessed 15 Feb 2019).</eref>

<jrn>8 Greenhalgh T, Howick J, Maskrey N; Evidence Based Medicine Renaissance Group. Evidence based medicine: a movement in crisis? *BMJ* 2014;348:g3725. [PubMed](#) doi:10.1136/bmj.g3725 </jrn>

<jrn>9 Goldacre B, Heneghan C. How medicine is broken, and how we can fix it. *BMJ* 2015;350:h3397. [PubMed](#) doi:10.1136/bmj.h3397 </jrn>

<jrn>10 Kirkham JJ, Altman DG, Chan A-W, Gamble C, Dwan KM, Williamson PR. Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews. *BMJ* 2018;362:k3802. [PubMed](#) doi:10.1136/bmj.k3802 </jrn>

<jrn>11 Cohen D. FDA official: “clinical trial system is broken”. *BMJ* 2013;347:f6980. [PubMed](#) doi:10.1136/bmj.f6980 </jrn>

<jrn>12 Roseman M, Turner EH, Lexchin J, Coyne JC, Bero LA, Thombs BD. Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. *BMJ* 2012;345:e5155. [PubMed](#) doi:10.1136/bmj.e5155 </jrn>

<jrn>13 Yudkin JS, Lipska KJ, Montori VM. The idolatry of the surrogate. *BMJ* 2011; **343**.</jrn>

<jrn>14 Greenland S, Senn SJ, Rothman KJ, et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. *Eur J Epidemiol* 2016;31:337-50. [PubMed](#) doi:10.1007/s10654-016-0149-3 </jrn>

<jrn>15 Christodoulou E, Ma J, Collins GS, Steyerberg EW, Verbakel JY, van Calster B. A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models. *J Clin Epidemiol* 2019;S0895-4356(18)31081-3. [PubMed](#)</jrn>

<eref>16 MiRoR. Interview with Professor Doug Altman. Projet MiRoR. 2018.<http://miror-ejd.eu/2018/03/20/interview-with-professor-doug-altman/> (accessed 14 Feb 2019).</eref>

<jrn>17 Straus SE, Haynes RB. David Sackett's legacy includes evidence-based mentorship. *J Clin Epidemiol* 2016;73:61-3. PubMed doi:10.1016/j.jclinepi.2016.02.015 </jrn>